110 filings
8-K
RSLS
ReShape Lifesciences Inc.
10 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:57pm
8-K
RSLS
ReShape Lifesciences Inc.
9 Apr 24
Changes in Registrant's Certifying Accountant
7:32pm
8-K
RSLS
ReShape Lifesciences Inc.
4 Apr 24
Completed First Surgeries With Next-Generation Lap-Band® 2.0 FLEX
11:12am
8-K
RSLS
ReShape Lifesciences Inc.
26 Feb 24
Submission of Matters to a Vote of Security Holders
4:19pm
8-K
RSLS
ReShape Lifesciences Inc.
18 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:38pm
8-K
9orcuekxlh1kyja sy59
29 Nov 23
Entry into a Material Definitive Agreement
4:05pm
8-K
z2oh22j5lpk 2fm1sc3
8 Nov 23
Third Quarter Core Operating Expenses Reduced 37% Compared to Third Quarter of 2022
5:44pm
8-K
0kmvcp 8f
13 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:42pm
8-K
z7gz wsndjhe
5 Oct 23
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
4:05pm
8-K
sj5hf dcpkw
22 Sep 23
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
4:02pm
8-K
nnzx azcr8u
7 Aug 23
Results of Operations and Financial Condition
4:54pm
8-K
i2i6h sn4
15 May 23
Executing a Plan For Growth and Profitability With a Balance Sheet Bolstered By Approximately $12.7 Million Raised in 2023
5:40pm
8-K
70v al02eg
26 Apr 23
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
4:06pm
8-K
xkw92 ocvj24fit04ar
13 Apr 23
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
5:24pm
8-K
jqy1 j018wc6ko
21 Mar 23
Entry into a Material Definitive Agreement
4:18pm
8-K
f2k8daoq9 u528n
10 Feb 23
ReShape Lifesciences Announces Pricing of Upsized
4:05pm
8-K
5lxi rn4xzx8
27 Jan 23
Other Events
6:06am
8-K
4oh70p 9bv9us
28 Dec 22
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split
4:18pm
8-K
ptihm5
20 Dec 22
Departure of Directors or Certain Officers
5:30pm
8-K
twedoqt
14 Nov 22
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:54pm